Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1β receptor antagonist (anakinra): An unrecognized autoinflammatory disease?
Article first published online: 30 DEC 2008
Copyright © 2008 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 60, Issue 1, pages 264–268, January 2009
How to Cite
Picco, P., Brisca, G., Traverso, F., Loy, A., Gattorno, M. and Martini, A. (2009), Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1β receptor antagonist (anakinra): An unrecognized autoinflammatory disease?. Arthritis & Rheumatism, 60: 264–268. doi: 10.1002/art.24174
- Issue published online: 30 DEC 2008
- Article first published online: 30 DEC 2008
- Manuscript Accepted: 25 SEP 2008
- Manuscript Received: 28 MAY 2008
Recurrent pericarditis occurs in association with various medical conditions, but in most cases the condition appears to be idiopathic. Although high-dose steroid treatment is often effective, it may have serious side effects. Herein we describe 3 children with recurrent pericarditis who were treated at our hospital, during flares, with the interleukin-1β receptor antagonist anakinra, with immediate response. Pericarditis recurred when anakinra treatment was discontinued, and no further episodes occurred after it was resumed. Idiopathic recurrent pericarditis shares several features with autoinflammatory diseases, and anakinra has been efficacious in the treatment of the latter diseases. The findings in these patients suggest that idiopathic recurrent pericarditis may be a previously unrecognized autoinflammatory disease.